临床试验:培戈扎非明对经活检证实的非酒精性脂肪性肝炎受试者肝脏及代谢合并症的影响
这项在美国16个中心开展的概念验证、开放标签、单队列1b/2a期试验第2部分,纳入20例经活检确诊的非酒精性脂肪性肝炎(NASH)成人受试者,每周一次皮下注射培戈扎非明27 mg,共20周。结果显示63%的受试者达到NAFLD活动度评分改善≥2分且气球样变或小叶炎症改善≥1分、纤维化无恶化的主要终点,MRI-PDFF较基线最小二乘均值相对变化为-64.7%(95% CI:-71.7,-57.7;p<0.0001),安全性和耐受性良好。
要点
- 20例经活检确诊的NASH受试者接受培戈扎非明27 mg每周一次皮下注射共20周。
- 63%的受试者达到NAFLD活动度评分改善≥2分且气球样变或小叶炎症改善≥1分、纤维化无恶化的主要终点。
- MRI-PDFF较基线最小二乘均值相对变化为-64.7%(95% CI:-71.7,-57.7;p<0.0001)。
核心结论
- 培戈扎非明治疗20周对NASH受试者的肝脏和代谢参数有有益影响,且耐受性良好。
研究设计与样本
- 概念验证、开放标签、单队列研究,为1b/2a期临床试验的第2部分,在美国16个中心开展。
- 纳入年龄21-75岁、经活检确诊NASH(纤维化2或3期,NAS≥4)且MRI-PDFF≥8%的成人受试者,共20例入组,19例完成研究。
主要发现
- 12例受试者(63%)达到主要终点:NAFLD活动度评分改善≥2分且气球样变或小叶炎症改善≥1分、纤维化无恶化。
- 26%的受试者观察到纤维化改善且NASH无恶化,32%的受试者观察到NASH缓解且纤维化无恶化。
- MRI-PDFF较基线最小二乘均值相对变化为-64.7%(95% CI:-71.7,-57.7;p<0.0001)。
- 血清转氨酶、无创纤维化检测、血清血脂、血糖控制和体重较基线均有显著改善。
- 18例受试者(90%)报告不良事件,最常见为轻度/中度恶心和腹泻;无严重不良事件、因不良事件停药或死亡。
关键数值与推荐
- 受试者接受培戈扎非明27 mg每周一次皮下注射,共20周。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: An approved therapy for nonalcoholic steatohepatitis (NASH) and fibrosis remains a major unmet medical need. AIM: To investigate the histological and metabolic benefits of pegozafermin, a glycoPEGylated FGF21 analogue, in subjects with biopsy-confirmed NASH. METHODS: This proof-of-concept, open-label, single-cohort study, part 2 of a phase 1b/2a clinical trial, was conducted at 16 centres in the United States. Adults (age 21-75 years) with NASH (stage 2 or 3 fibrosis, NAS≥4) and magnetic resonance imaging proton density fat fraction (MRI-PDFF) ≥8% received subcutaneous pegozafermin 27 mg once weekly for 20 weeks. Primary outcomes were improvements in liver histology, and safety and tolerability. RESULTS: Of 20 enrolled subjects, 19 completed the study. Twelve subjects (63%) met the primary endpoint of ≥2-point improvement in NAFLD activity score with ≥1-point improvement in ballooning or lobular inflammation and no worsening of fibrosis. Improvement of fibrosis without worsening of NASH was observed in 26% of subjects, and NASH resolution without worsening of fibrosis in 32%. Least-squares mean relative change from baseline in MRI-PDFF was -64.7% (95% CI: -71.7, -57.7; p < 0.0001). Significant improvements from baseline were also seen in serum aminotransferases, noninvasive fibrosis tests, serum lipids, glycaemic control and body weight. Adverse events (AEs) were reported in 18 subjects (90%). The most frequently reported AEs were mild/moderate nausea and diarrhoea. There were no serious AEs, discontinuations due to AEs, or deaths. CONCLUSIONS: Pegozafermin treatment for 20 weeks had beneficial effects on hepatic and metabolic parameters and was well tolerated in subjects with NASH. CLINICALTRIALS: gov: NCT04048135.
引用
- Alkhouri N, Lazas D, Loomba R, et al. Clinical trial: Effects of pegozafermin on the liver and on metabolic comorbidities in subjects with biopsy-confirmed nonalcoholic steatohepatitis. Aliment Pharmacol Ther. 2023. PMID: 37718721. doi:10.1111/apt.17709
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。